| HOME >> BIOLOGY >> TECHNOLOGY |
HONG KONG, Nov. 1, 2011 /PRNewswire/ -- OrbusNeich today announced that data from REMEDEE (Randomized Evaluation of an abluMinal sirolimus coatED bio-Engineered stEnt), a randomized clinical trial of the Combo Bio-engineered Sirolimus Eluting Stent (Combo Dual Therapy Stent), will be presented in the Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011 in San Francisco. The presentation entitled "REMEDEE: A Prospective, Randomized Trial of a Combination Bioabsorbalble Polymer-based Anti-CD34 Antibody Sirolimus-Eluting Stent vs. a Durable Polymer-based Paclitaxel-Eluting Stent" by Michael Haude, M.D., of Medical Clinic I at the Lukaskrankenhaus in Neuss, Germany, will take place at 11:10 a.m. PST on Nov. 11 in the main arena.
The REMEDEE trial was designed to demonstrate the safety and effectiveness of the Combo Dual Therapy Stent compared to the TAXUS® Liberte® paclitaxel-eluting stent in patients with symptomatic, ischemic heart disease due to a stenotic lesion located in a native coronary artery. This objective was measured in patients by a comparison of in-stent late lumen loss at nine months post-procedure. The trial included 183 patients at sites in Asia, Australia, Europe and South America.
On Thursday, Nov. 10, the Combo Dual Therapy Stent will be featured in a REMEDEE Breakfast Symposium titled "The New Combo Dual Therapy Stent." The symposium will be chaired by Martin B. Leon, M.D., and Alexandre Abizaid, M.D., and will take place at 7 a.m. PST in room 120. The symposium will provide an overview of the stent's underlying pro-healing technology, Genous, and the rationale of the REMEDEE study. Dr. Leon will introduce the new category of dual therapy stents, Roxana Mehran, M.D., will discuss the need for novel stents, Dr. Abizaid will describe the technology behind the Combo Dual Therapy Stent, and Michael Haude, M.D., wil
'/>"/>
| SOURCE OrbusNeich Copyright©2010 PR Newswire. All rights reserved |